Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  AVEO Pharmaceuticals, Inc.    AVEO   US0535881090

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

AVEO Pharmaceuticals, Inc. : DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders of AVEO Pharmaceuticals, Inc. of Upcoming Deadline

06/25/2013 | 05:25pm US/Eastern

Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of AVEO Pharmaceuticals, Inc. (NASDAQ GS: AVEO)?
  • Did you purchase your shares before January 3, 2012, or between January 3, 2012 and May 1, 2013, inclusive?
  • Did you lose money in your investment in AVEO Pharmaceuticals, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, reminds shareholders of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ GS: AVEO) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

A complaint was filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities that purchased the common stock of AVEO between January 3, 2012 and May 1, 2013, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint"). If you wish to serve as lead plaintiff, you must move the Court no later than July 8, 2013.

If you purchased shares of AVEO during the Class Period, or purchased shares prior to the Class Period and still hold AVEO, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/aveo-pharmaceuticals-inc-aveo.

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
info@rigrodskylong.com
http://www.rigrodskylong.com


© Business Wire 2013
React to this article
Latest news on AVEO PHARMACEUTICALS, INC.
07:01a AVEO PHARMACEUTICALS : Oncology : Announces Additional Biomarker Analyses from B..
06/11 AVEO PHARMACEUTICALS : Announces FDA Update for Tivozanib in Colorectal Cancer
06/03 AVEO PHARMACEUTICALS : Announces Receipt of European Regulatory Guidance Regardi..
06/03 AVEO PHARMACEUTICALS : Change in Directors or Principal Officers, Amendments to ..
05/29 AVEO PHARMACEUTICALS : Oncology : to Present at Jefferies 2015 Global Healthcare..
05/26 AVEO PHARMACEUTICALS : Oncology : Announces New Corporate Headquarters in Cambri..
05/20 AVEO PHARMACEUTICALS : Oncology : Announces Presentation of Final Results of Ext..
05/07 AVEO PHARMACEUTICALS : Oncology : Reports First Quarter 2015 Financial Results
04/24 AVEO PHARMACEUTICALS : Recent Developments in the Pharma Sector: Complementary R..
04/22 AVEO PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
Advertisement
Chart
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | AVEO | US0535881090 | 4-Traders
Income Statement Evolution
More Financials